Gero
Singapore, Singapore· Est.
AI‑driven, physics‑based drug discovery platform targeting the root causes of human aging.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
AI‑driven, physics‑based drug discovery platform targeting the root causes of human aging.
AgingFibrosisNeurodegeneration
Technology Platform
Physics‑informed generative AI (Large Health Model) trained on >100 M longitudinal health records, enabling causal pathway discovery and structure‑free drug design.
Opportunities
Gero’s AI‑driven platform can accelerate target identification for a broad array of age‑related diseases, opening multi‑billion‑dollar markets and attractive partnership opportunities with large pharma.
Risk Factors
The core scientific hypothesis—physics‑based separation of aging from disease—remains unvalidated in humans, and regulatory pathways for aging‑modifying therapies are uncertain, posing significant execution risk.
Competitive Landscape
Key competitors include Calico, Unity Biotechnology, and Alkahest; Gero differentiates itself through a physics‑informed, interpretable AI model and a focus on systemic resilience rather than single‑pathway interventions.